---
schema_version: "secwatch.filing_event.v1"
accession: "0001000694-23-000059"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T05:59:50.238208+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Novavax Q3 revenue $187M (down 75% YoY); FY23 revenue guidance lowered to $900M-$1.1B

## Summary
- Q3 2023 total revenue $187M vs $735M YoY; net loss $131M improved from $169M loss YoY.
- FY2023 total revenue guidance cut to $900M-$1.1B from prior $1.3B-$1.5B; expects additional $300M in Q1 2024.
- Additional cost reduction of >$300M in 2024 targeting R&D/SG&A <$750M and >$100M supply network savings.
- Received FDA EUA for updated COVID-19 vaccine Oct 2023; available at ~14,000 U.S. pharmacy locations.
- WHO recommended R21/Matrix-M malaria vaccine; initial Matrix-M sales recognized in Q3 2023.

## SEC filing metadata
- accession: 0001000694-23-000059
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000100069423000059/0001000694-23-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000100069423000059/nvax-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001000694-23-000059
- JSON: https://secwatch.observer/filing/0001000694-23-000059.json
- Plain text: https://secwatch.observer/filing/0001000694-23-000059.txt

## Key facts
- Earnings Releases
  NOVAVAX INC reported the third quarter ended September 30, 2023 results: revenue $187 million, net income Net loss of $131 million.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $187 million
  - Net income: Net loss of $131 million
  - Result: reported results
  source text: received recommendation from the World Health Organization; launch expected in 2024 2 Third Quarter 2023 Financial Results • Total revenue for the third quarter of 2023 was $187 million, compared to $735 million in the same period in 2022. Third quarter 2023 grant revenue of $165 million benefited from milestone achievements related to U.S. market preparedness
  evidence_url: https://www.sec.gov/Archives/edgar/data/1000694/000100069423000059/0001000694-23-000059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.